GOVX - GeoVax Labs, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.0105
-0.0010 (-8.70%)
At close: 3:57PM EDT
Stock chart is not supported by your current browser
Previous Close0.0115
Open0.0120
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.0096 - 0.0123
52 Week Range0.0096 - 15.0000
Volume7,208,532
Avg. Volume753,173
Market Cap28,114
Beta (3Y Monthly)1.59
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • ACCESSWIRE

    Leveraging GeoVax's Vaccine Expertise To Take On Cancer

    ATLANTA, GA / ACCESSWIRE / September 9, 2019 / GeoVax Labs, Inc. (GOVX), a biotechnology company developing human immunotherapies and vaccines has historically been associated with the development of vaccines against infectious diseases. The company is now leveraging the knowledge and expertise it has validated in infectious diseases and expanding the applicability of MVA-VLP into immuno-oncology (IO) with highly promising results. GeoVax Labs, Inc. is a clinical-stage biotechnology company developing human vaccines against infectious diseases and cancer using a novel patented Modified Vaccinia Ankara-Virus Like Particle (MVA-VLP) based vaccine platform.

  • GlobeNewswire

    GeoVax Announces Publication of Lassa Fever Vaccine Study Results

    ATLANTA, GA, Sept. 04, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- GeoVax Labs, Inc. (GOVX), a biotechnology company developing human vaccines, today announced publication of its article entitled “A Single Dose of Modified Vaccinia Ankara Expressing Lassa Virus-like Particles Protects Mice from Lethal Intra-cerebral Virus Challenge.” The paper appears in the open access journal Pathogens published by MDPI, based in Basel, Switzerland, and can be viewed at https://www.mdpi.com/2076-0817/8/3/133. GeoVax’s Lassa fever vaccine (GEO-LM01) is based on the Company’s novel Modified Vaccinia Ankara (MVA) Virus-Like Particle (VLP) platform, which generates noninfectious VLPs in the individual being vaccinated.

  • GlobeNewswire

    GeoVax Reports 2019 Second Quarter Financial Results and Highlights Corporate Development Progress

    ATLANTA, Aug. 14, 2019 -- via NEWMEDIAWIRE -- GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing human immunotherapies and vaccines, today announced its.

  • GlobeNewswire

    GeoVax Issues Shareholder Update Letter

    Updates Provided on Financial Status and Development Programs ATLANTA, GA, Aug. 02, 2019 -- via NEWMEDIAWIRE -- GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company.

  • GlobeNewswire

    GeoVax Addresses WHO Declaration of Ebola Outbreak as Global Public Health Emergency

    ATLANTA, GA, July 30, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- GeoVax Labs, Inc. (GOVX), a biotechnology company developing human vaccines and immunotherapies, today responded to the World Health Organization’s (WHO) recent declaration of the Ebola outbreak in the Democratic Republic of the Congo (DRC) as a global public health emergency.  The Company is offering its novel Ebola preventive vaccine (GEO-EM01), gratis, for public health use, contingent upon WHO or related agencies advancing the vaccine into human clinical evaluation.  GeoVax believes its vaccine to be distinctly superior to the experimental vaccine currently in use in failing attempts to contain the epidemic. GeoVax has demonstrated that a single intramuscular (IM) dose of GEO-EM01 provided 100% protection in rhesus macaques challenged with a lethal dose of Ebola virus (EBOV).

  • GlobeNewswire

    GeoVax Announces 100% Protection Data from Marburg Virus Vaccine Study

    Study Data Adds to Similar Efficacy Previously Reported for GeoVax’s Ebola and Lassa Fever Vaccines ATLANTA, GA, July 29, 2019 -- via NEWMEDIAWIRE – GeoVax Labs, Inc. (OTCQB:.

  • GlobeNewswire

    GeoVax Presents HIV Vaccine Study Data

    Presentation Made at the 10th International AIDS Society Conference on HIV Science ATLANTA, GA, July 24, 2019 -- via NEWMEDIAWIRE -- GeoVax Labs, Inc. (OTCQB: GOVX), a.

  • GlobeNewswire

    GeoVax Announces Upcoming Presentation of Lassa Fever Vaccine Data

    ATLANTA, GA, July 16, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- GeoVax Labs, Inc. (GOVX), a biotechnology company specializing in developing human vaccines, announced today that Senior Scientist, Mugdha Vasireddi, PhD, will deliver an oral presentation entitled, A Single Dose of MVA-Based Lassa Virus Vaccine Provides Complete Protection in a Mouse Lethal Challenge Model. The presentation will be given during the Annual Meeting of the American Society for Virology, being held July 20-24 in Minneapolis, Minnesota. In her talk, Dr. Vasireddi will discuss the preclinical efficacy studies of GEO-LM01, a novel vaccine candidate for Lassa fever constructed on an MVA vector expressing two immunogens derived from the Lassa virus.

  • GlobeNewswire

    GeoVax Reports 2019 First Quarter Financial Results and Highlights Corporate Development Progress

    ATLANTA, May 14, 2019 -- GeoVax Labs, Inc. (OTCQB: GOVXD), a biotechnology company developing human vaccines, today announced its financial results for the three months ended.

  • GlobeNewswire

    Update: GeoVax Announces Reverse Stock Split

    1:500 Reverse Split Effective May 2, 2019;Ticker Symbol Changed to GOVXD for 20 Days ATLANTA, GA , May 03, 2019 -- via NEWMEDIAWIRE -- GeoVax Labs, Inc. (OTCQB: GOVX) today.

  • GlobeNewswire

    GeoVax Announces Reverse Stock Split

    1:500 Reverse Split Effective May 2, 2019;Ticker Symbol Changed to GOVXD for 20 Days ATLANTA, GA, May 03, 2019 -- via NEWMEDIAWIRE -- GeoVax Labs, Inc. (OTCQB: GOVX).

  • GlobeNewswire

    GeoVax Recognizes World Malaria Day 2019

    ATLANTA, GA, April 25, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- GeoVax Labs, Inc. (GOVX) today is observing World Malaria Day, an annual international event held on April 25th each year to recognize global efforts to control and ultimately eradicate malaria.  GeoVax is commemorating World Malaria Day 2019 by highlighting the efforts of its scientists and collaborators toward the development of a much-needed effective vaccine against this disease. Malaria is a mosquito-borne disease caused by Plasmodium parasites. Nearly half of the world’s population (over 3 billion people) are at risk of malaria infection.

  • GlobeNewswire

    GeoVax Reports 2018 Year-End Financial Results

    ATLANTA, March 27, 2019 -- GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing human vaccines, today announced its financial results for the year ended December.

  • GlobeNewswire

    GeoVax Ebola Vaccine Study Published in the Atlas of Science

    GeoVax Ebola Vaccine Provides Potential for 100% Protection from Single-Dose ATLANTA, GA, March 19, 2019 -- via NEWMEDIAWIRE -- GeoVax Labs, Inc. (OTCQB: GOVX), a.

  • GlobeNewswire

    GeoVax Selected as Finalist for Vaccine Industry Excellence Awards

    Selection in Two Award Categories follows GeoVax receiving the 2018 Best Biotech Award ATLANTA, GA, March 12, 2019 -- via NEWMEDIAWIRE -- GeoVax Labs, Inc. (OTCQB: GOVX), a.

  • GlobeNewswire

    GeoVax Provides Product Development and Corporate Update

    ATLANTA, GA, March 11, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – GeoVax Labs, Inc. (GOVX), a biotechnology company developing human vaccines and immunotherapies using its novel viral vector platform technology, today provided an update on its progress and development programs. David Dodd, GeoVax President and CEO, commented, “We continue to advance GeoVax’s development programs on multiple fronts with an expanding list of world-class government, academic and corporate collaborators, as further described in this update. Going forward, we will continue to evaluate options to secure the capital needed to proceed with our business plan, especially to advance further programs into human clinical testing.

  • GlobeNewswire

    GeoVax and Leidos Expand Collaboration to Malaria Vaccines

    Supported by Contract from U.S. Agency for International Development (USAID) ATLANTA, GA, March 04, 2019 -- via NEWMEDIAWIRE -- GeoVax Labs, Inc. (OTCQB: GOVX), a.

  • GlobeNewswire

    GeoVax Issues Open Letter to HHS Secretary Alex Azar

    Comments on HHS Initiative “Ending the HIV Epidemic: A Plan for America” ATLANTA, GA, Feb. 14, 2019 -- via NEWMEDIAWIRE -- GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology.

  • GeoVax Recognizes National Black HIV/AIDS Awareness Day
    GlobeNewswire

    GeoVax Recognizes National Black HIV/AIDS Awareness Day

    Today, individuals and organizations across the country will observe National Black HIV/AIDS Awareness Day. GeoVax is commemorating the day by celebrating the progress toward the development of a vaccine against HIV, recognizing the work yet to be done, and bringing attention to the continued HIV epidemic in the United States and the disproportionate impact of the disease on African-Americans.

  • GlobeNewswire

    GeoVax CEO David Dodd Responds to President Trump’s State of the Union Message

    During Tuesday night’s State of the Union address, President Donald Trump asked Congress to support his goal of eliminating the HIV epidemic in America within 10 years. GeoVax’s President and CEO, David Dodd, responded today. “We applaud President Trump for using such a high-profile setting to bring attention to the continued HIV epidemic in the United States,” Mr. Dodd commented.

  • GlobeNewswire

    GeoVax Zika Vaccine Study Published in the Atlas of Science

    GeoVax Zika Vaccine Provides Potential for 100% Protection & Reduced Side-Effect Risks ATLANTA, GA, Jan. 24, 2019 -- via NEWMEDIAWIRE -- GeoVax Labs, Inc. (OTCQB: GOVX), a.

  • GlobeNewswire

    GeoVax to Present at the 2019 ASM Biothreats Conference

    ATLANTA, GA, Jan. 22, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- GeoVax Labs, Inc. (GOVX), a biotechnology company developing human vaccines, announced that Senior Scientist, Mary Hauser, PhD, will deliver a presentation, entitled “Development of a Safe and Effective Single-Dose Vaccine for Emerging Infectious Diseases, Preclinical Data for Zika, Ebola and Lassa Fever as Examples,” during the 2019 American Society for Microbiology (ASM) Biothreats Conference, being held January 29-31, 2019 in Arlington, Virginia. Dr. Hauser will discuss GeoVax’s “Plug and Play” vaccine platform which utilizes its recombinant Modified Vaccinia Ankara (MVA) vector to express foreign antigens on virus-like particles (VLPs) in the person being vaccinated. The MVA-VLP platform has several advantages including the ability to use single inoculations to achieve full protection.

  • GeoVax and Enesi Pharma to Collaborate on Development of Multiple Vaccines Administered by ImplaVax®, a Novel Needle-Free Vaccine Delivery Platform
    GlobeNewswire

    GeoVax and Enesi Pharma to Collaborate on Development of Multiple Vaccines Administered by ImplaVax®, a Novel Needle-Free Vaccine Delivery Platform

    Potential for Addressing Multiple Infectious Disease Targets ATLANTA, GA and OXFORD, UK, Jan. 02, 2019 -- via NEWMEDIAWIRE -- GeoVax Labs, Inc. (OTCQB: GOVX), a.

  • GlobeNewswire

    GeoVax Comments on 2018 Ebola Outbreak

    David Dodd, GeoVax President and CEO, stated, “The ongoing Ebola outbreak in DRC is now among the deadliest in history, second only to the 2014-16 outbreak in several African nations that infected 28,652 people and killed 11,325. As of December 8, 2018, there have been 446 confirmed cases of Ebola in the Congo with 235 deaths, which disproportionally affected women and young children. There is currently no licensed vaccine to protect people from the Ebola virus. An experimental vaccine with a limited supply is being used in a “ring vaccination” approach.

  • GeoVax Observes 2018 World AIDS Day
    GlobeNewswire

    GeoVax Observes 2018 World AIDS Day

    World AIDS Day is a global initiative to raise awareness, fight prejudice, and improve education about HIV and AIDS. “The U.S. federal theme for the 2018 World AIDS Day observance is Saving Lives through Leadership and Partnerships,” commented David Dodd, President & CEO of GeoVax. “GeoVax is committed to an AIDS-free generation through vaccine development, and today we would like to recognize and thank our many collaborators and partners, both current and past, who have helped advance our vaccine candidates.